SCHEMBL3265027

SCHEMBL3265027

CC(=O)OCCn1nc(NC(=O)c2ccc(F)cc2)c2cc(F)c(-c3cnn4c(C)cccc34)nc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.41
NPSR1 Q6W5P4 2/20 0.41
ALDH1A1 P00352 5/20 0.37
KDM4E B2RXH2 4/20 0.37
MAPT P10636 4/20 0.37
ATM Q13315 3/20 0.37
L3MBTL1 Q9Y468 3/20 0.37
MAPK1 P28482 2/20 0.37
CASP1 P29466 1/20 0.37
USP2 O75604 1/20 0.36
NPC1 O15118 2/20 0.36
TP53 P04637 3/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
POLB P06746 2/20 0.35
PAX8 Q06710 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
RAB9A P51151 1/20 0.34
GAA P10253 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8045946 0.93 NPSR1 (0.34) LMNANPSR1ALDH1A1KDM4EMAPT
SCHEMBL7948913 0.88 LMNA (0.41) LMNANPSR1ALDH1A1KDM4EMAPT
SCHEMBL3262282 0.83 KDR (0.34) ALDH1A1
SCHEMBL8049800 0.83 KDM4E (0.42) LMNANPSR1ALDH1A1KDM4EMAPT
SCHEMBL3259592 0.83 NPC1 (0.38) LMNAALDH1A1KDM4EMAPTATM
SCHEMBL13099802 0.82 ALDH1A1 (0.39) LMNANPSR1ALDH1A1KDM4EMAPT
SCHEMBL7955204 0.81 ATM (0.39) NPSR1ALDH1A1KDM4EMAPTATM
SCHEMBL3107285 0.79 KDM4E (0.39) LMNANPSR1ALDH1A1KDM4EMAPT
SCHEMBL13099805 0.78 LMNA (0.42) LMNAALDH1A1KDM4EMAPTL3MBTL1
SCHEMBL13099793 0.78 AXL (0.38) ALDH1A1KDM4EATML3MBTL1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256133-A1 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHOONGWAE PHARMA CORPORATION (KR) 2010-10-07 US disclosed
US-20100256133-A1 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHOONGWAE PHARMA CORPORATION (KR) 2010-10-07 US disclosed
US-20100256133-A1 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHOONGWAE PHARMA CORPORATION (KR) 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256133-A1 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME MAP3K20, MAP3K3, MAP3K1 LMNA 2434/4885NPSR1 3864/4885ALDH1A1 2584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.